Prelude Therapeutics Incorporated develops novel precision cancer medicines for underserved patients. PRT543 targets select solid tumors and myeloid malignancies; PRT811 targets solid tumors, including glioblastoma multiforme. Prelude Therapeutics was founded in 2016 and is headquartered in Wilmington, DE.
Name / Ticker | Price | Zen Rating |
---|---|---|
$8.05 | A | |
$45.72 | A | |
$22.07 | A |